Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors (PPIs)

Observational Study of More than 53,000 Americans Suggests an Association Between PPIs and Risk of COVID-19
American College of Gastroenterology (ACG)

Newswise — (Bethesda, MD, July 7, 2020) Findings from an online survey of more than 53,000 Americans suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appears online today in pre-print format in The American Journal of Gastroenterology.

Researchers Christopher V. Almario, MD, MSHPM and Brennan M. R. Spiegel, MD, MSHS, FACG of Cedars-Sinai in Los Angeles along with William D. Chey, MD, FACG of the University of Michigan conducted a large population-based, online survey to evaluate whether use of PPIs increases risk of COVID-19.

“We developed this hypothesis at the beginning of the COVID-19 pandemic when we started to see a high incidence of GI symptoms and learned that the virus sheds into saliva, and thus can be swallowed into the stomach. We have now tested the hypothesis in a rigorous study of more than 50,000 Americans and found it to bear out, albeit in an observational study,” commented Dr. Almario.

According to the investigators, PPIs increase the risk for enteric infections which is likely related to PPI-induced hypochlorhydria, or low levels of gastric acid. “Although the impact of acid suppression on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown thus far, prior data revealed that pH ≤3 impairs the infectivity of the similar SARS-CoV-1. Thus, we aimed to determine whether use of PPIs increases the odds for acquiring COVID-19 among community-dwelling Americans,” they write.

Of 53,130 participants, 3,386 (6.4%) reported a positive COVID-19 test. In regression analysis, individuals using PPIs up to once daily (OR 2.15; 95% CI, 1.90–2.44) or twice daily (OR 3.67; 95% CI, 2.93–4.60) had significantly increased odds for reporting a positive COVID-19 test when compared to those not taking PPIs. Individuals taking histamine-2 receptor antagonists (H2RAs) were not at elevated risk.

“There is a reason we have acid in our stomach, namely, to kill pathogens before they enter the digestive tract,” commented Dr. Spiegel, Co-Editor-in Chief of The American Journal of Gastroenterology. “Coronaviruses are easily destroyed at a gastric pH of less than 3, but survive in a more neutral pH, including the range created by drugs like omeprazole and esomeprazole.”

“We found a strong, independent effect of using PPIs on risk of COVID-19, including a dose-response relationship with nearly a four-fold increased risk for twice daily dosing. But we found no relationship with the less powerful H2RAs, such as  famotidine or cimetidine,” he added.

According to Dr. Spiegel, “previous research has already demonstrated that PPIs slightly increase the risk of enteric infections, but the strong link found here speaks to COVID-19 pathogenesis through the GI tract, where the expression of the receptors the virus uses to enter the body, known as ACE-2 receptors, is roughly 100-fold higher than in any other part of the body, including the lungs.”

While these data arise from a large sample, demonstrate a large effect size, reveal a dose-response relationship, are controlled for confounders, and are different from a control group using H2RAs, all strengthening the results, the investigators note that further studies examining the association between PPIs and COVID-19 are needed.

Brian E. Lacy, MD, PhD, FACG, Co-Editor-in-Chief of The American Journal of Gastroenterology commented, “The results of this large survey study, from an experienced team of clinicians and researchers, are intriguing and add novel, clinically relevant information to the rapidly evolving field of COVID-19 during this devastating pandemic. Prior research studies have shown that PPIs slightly increase the risk of an infection developing in the gastrointestinal tract. We now recognize that receptors for COVID-19, (ACE-2) are found throughout the gastrointestinal tract, which supports the biologic plausibility that PPI use could be associated with an increased risk for COIVD-19. However, as the authors carefully point out in their thoughtful analysis, this is not a randomized, placebo-controlled study, but rather a study demonstrating an association, and thus studies from other groups should be analyzed to confirm these novel findings.”

Patients who take PPIs should not make any changes in their treatment due to this study without consulting with their physician, especially if the patients need PPIs to treat their digestive disorders. Everyone should be mindful about the spread of COVID-19 and wear a mask, observe social distancing, and meticulously wash or sanitize their hands.

Information Sheet and FAQs About Proton Pump Inhibitors (PPIs) and Risk of COVID-19

The authors provide more information about this research in the form of Frequently Asked Questions (FAQ) here.

The full study in pre-print format can be found here. Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol 2020 (pre-print posted online July 7, 2020)

About The American Journal of Gastroenterology

Published monthly since 1934, The American Journal of Gastroenterology (AJG) is the official peer-reviewed journal of the American College of Gastroenterology. The goal of the Journal is to publish scientific papers relevant to the practice of clinical gastroenterology. It features original research, review articles, and consensus papers related to new drugs and therapeutic modalities. The AJG Editorial Board encourages submission of original manuscripts, review articles, and letters to the editor from members and non-members. AJG is published by Wolters Kluwer. www.amjgastro.com

About the American College of Gastroenterology

Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of more than 15,000 individuals from 85 countries. The College's vision is to be the pre-eminent professional organization that champions the evolving needs of clinicians in the delivery of high-quality, evidence-based, and compassionate health care to gastroenterology patients. The mission of the College is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation, and advocacy in the areas of scientific investigation, education, prevention, and treatment. www.gi.org Follow ACG on Twitter @AmCollegeGastro

# # #



Filters close

Showing results

110 of 6133
Released: 5-Aug-2021 2:30 PM EDT
Research Shows Many with Mild COVID-19 Infections Still Experience Long-Term Symptoms
University of Arizona Health Sciences Center

The majority of individuals who experience mild or moderate COVID-19 infection also experience long COVID, or persistent symptoms more than 30 days after they test positive, according to research data from the longitudinal CoVHORT study at the University of Arizona Health Sciences.

Released: 5-Aug-2021 2:10 PM EDT
Should COVID-19 Vaccination Be Mandatory for Health and Care Staff?
BMJ

Italy, France, and Greece have made covid-19 vaccination mandatory for healthcare workers, and England is making it compulsory for care home workers and consulting on whether to extend this to healthcare workers and other social care staff.

Newswise: Organ Transplant Recipients Significantly Protected by COVID-19 Vaccination
Released: 5-Aug-2021 1:55 PM EDT
Organ Transplant Recipients Significantly Protected by COVID-19 Vaccination
University of California San Diego Health

UC San Diego researchers report that solid organ transplant recipients who were vaccinated experienced an almost 80 percent reduction in the incidence of symptomatic COVID-19 compared to unvaccinated counterparts during the same time.

Newswise: Statement: Employers Need to Require COVID-19 Vaccination for Healthcare Workforce
Released: 5-Aug-2021 1:30 PM EDT
Statement: Employers Need to Require COVID-19 Vaccination for Healthcare Workforce
American Association of Critical-Care Nurses (AACN)

The American Association of Critical-Care Nurses calls for all healthcare and long-term-care employers to require every member of the healthcare team to be vaccinated against COVID-19, except when medically contraindicated.

Newswise: 17d548cf-cfe0-4673
Released: 5-Aug-2021 1:10 PM EDT
Heads Reveal How ‘Overwhelming’ Government Guidance Held Schools Back as COVID Hit
University of Cambridge

Headteachers and school leaders have described how an ‘avalanche’ of confused and shifting Government guidance severely impeded schools during the critical first months of COVID lockdown in a new study.

Released: 5-Aug-2021 10:55 AM EDT
AMSSM Partners with White House and 11 Organizations to Encourage Vaccine Conversations During Sports Physicals
American Medical Society for Sports Medicine (AMSSM)

AMSSM and 11 other leading sports and medical organizations signed on to a consensus statement to encourage healthcare providers to include conversations about COVID-19 vaccinations as part of the pre-participation physical.

Newswise: August Issue of Issue of The American Journal of Gastroenterology Includes Diet-Associated NAFLD Risk and Increased Risk of Mortality from COVID-19 Among PPI Users
Released: 5-Aug-2021 9:25 AM EDT
August Issue of Issue of The American Journal of Gastroenterology Includes Diet-Associated NAFLD Risk and Increased Risk of Mortality from COVID-19 Among PPI Users
American College of Gastroenterology (ACG)

The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.

Released: 5-Aug-2021 8:45 AM EDT
Research Reveals that Flu Shot Protects Against Severe Effects of COVID-19
University of Miami Health System, Miller School of Medicine

In a newly published study, physician-scientists at the University of Miami Miller School of Medicine have shown that the flu vaccine may provide vital protection against COVID-19.

Released: 5-Aug-2021 8:45 AM EDT
Persistent COVID-19 Infections in Immunocompromised People May Give Rise to Variants of Concern
Fred Hutchinson Cancer Research Center

In an article in the New England Journal of Medicine, scientists from Fred Hutchinson Cancer Research Center, Johns Hopkins Bloomberg School of Medicine, the U.S. Military HIV Research Program and the Institute for Global Health and Infectious Diseases at the University of North Carolina urged increased attention to persistent COVID-19 infections in immunocompromised people.

Newswise: Novel Model Predicts COVID-19 Outbreak Two Weeks Ahead of Time
Released: 5-Aug-2021 8:30 AM EDT
Novel Model Predicts COVID-19 Outbreak Two Weeks Ahead of Time
Florida Atlantic University

People’s social behavior, reflected in their mobility data, is providing scientists with a way to forecast the spread of COVID-19 nationwide at the county level. Researchers have developed the first data-driven deep learning model with the potential to predict an outbreak in COVID-19 cases two weeks in advance. Feeding the mobility data to epidemiological forecasting models helps to estimate COVID-19 growth as well as evaluating the effects of government policies such as mandating masks on the spread of COVID-19.


Showing results

110 of 6133

close
7.25552